Skip to main content
Premium Trial:

Request an Annual Quote

Canada Invests C$3M in Metabolomics Instruments

NEW YORK (GenomeWeb) – The Canadian Government today announced an investment of C$3 million (US$2.4 million) towards instruments to help establish the Metabolomics Technology Demonstration Centre, in partnership with Genome Alberta and the University of Alberta.

The instruments, a 700 MHz nuclear magnetic resonance machine and a quadrupole time-of-flight mass spectrometer, will assist companies in the metabolomics sector translate biomarker-based tests from the lab into the clinic. Companies will test, validate, and assemble prototypes using the University of Alberta Metabolomics Innovation Centre's biomarker panels, to create more accurate and less invasive medical tests.

"The Metabolomics Technology Demonstration Centre will provide Canadian researchers with cutting edge infrastructure and technical expertise to support translation of innovative biomarker discoveries into real life applications," David Wishart, professor of biological and computing sciences at the University of Alberta, said in a statement.

The National Institute of Nanotechnology, Alberta Innovates Health Solutions, Metabolomics Technologies, and Genome Canada are also contributors towards this project.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.